Living Cell Technologies Limited (LVCLF)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -3.1 Million AUD | 24.39% |
| 2023 | -4.11 Million AUD | 3.01% |
| 2022 | -4.23 Million AUD | -170.18% |
| 2021 | -1.56 Million AUD | 42.11% |
| 2020 | -2.71 Million AUD | 44.78% |
| 2019 | -4.9 Million AUD | 28.47% |
| 2018 | -6.86 Million AUD | 8.88% |
| 2017 | -7.53 Million AUD | -42.02% |
| 2016 | -5.3 Million AUD | -3.07% |
| 2015 | -5.14 Million AUD | -12.95% |
| 2014 | -4.55 Million AUD | -1.12% |
| 2013 | -4.5 Million AUD | -42.08% |
| 2012 | -3.17 Million AUD | 29.63% |
| 2011 | -4.5 Million AUD | -44.65% |
| 2010 | -3.11 Million AUD | -9.96% |
| 2009 | -2.83 Million AUD | 73.54% |
| 2008 | -10.7 Million AUD | -1771.78% |
| 2007 | -571.78 Thousand AUD | 43.75% |
| 2006 | -1.01 Million AUD | 61.23% |
| 2005 | -2.62 Million AUD | -560.46% |
| 2004 | 569.38 Thousand AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 FY | -3.1 Million AUD | 24.39% |
| 2024 Q1 | -622.44 Thousand AUD | 85.32% |
| 2024 Q3 | -808.41 Thousand AUD | 77.68% |
| 2024 Q4 | -3.1 Million AUD | -284.51% |
| 2024 Q2 | -3.62 Million AUD | -481.97% |
| 2023 FY | -4.11 Million AUD | 3.01% |
| 2023 Q4 | -4.23 Million AUD | -3.11% |
| 2023 Q1 | -3.08 Million AUD | 27.21% |
| 2023 Q2 | -3.08 Million AUD | 0.0% |
| 2023 Q3 | -4.11 Million AUD | -33.23% |
| 2022 FY | -4.23 Million AUD | -170.18% |
| 2022 Q4 | -4.23 Million AUD | 0.0% |
| 2022 Q3 | -4.23 Million AUD | 3.91% |
| 2022 Q2 | -4.41 Million AUD | 0.0% |
| 2022 Q1 | -4.41 Million AUD | -181.18% |
| 2021 Q3 | -1.56 Million AUD | 24.58% |
| 2021 Q4 | -1.56 Million AUD | 0.0% |
| 2021 Q1 | -2.13 Million AUD | 21.29% |
| 2021 Q2 | -2.08 Million AUD | 2.49% |
| 2021 FY | -1.56 Million AUD | 42.11% |
| 2020 Q2 | -3.19 Million AUD | 1.63% |
| 2020 FY | -2.71 Million AUD | 44.78% |
| 2020 Q3 | -2.76 Million AUD | 13.64% |
| 2020 Q1 | -3.25 Million AUD | 33.72% |
| 2020 Q4 | -2.71 Million AUD | 1.92% |
| 2019 Q1 | -5.42 Million AUD | 20.98% |
| 2019 FY | -4.9 Million AUD | 28.47% |
| 2019 Q2 | -5.42 Million AUD | 0.0% |
| 2019 Q3 | -4.9 Million AUD | 9.49% |
| 2019 Q4 | -4.9 Million AUD | 0.0% |
| 2018 Q4 | -6.86 Million AUD | 0.0% |
| 2018 Q3 | -6.86 Million AUD | -30.75% |
| 2018 Q2 | -5.24 Million AUD | 0.0% |
| 2018 Q1 | -5.24 Million AUD | 30.31% |
| 2018 FY | -6.86 Million AUD | 8.88% |
| 2017 FY | -7.53 Million AUD | -42.02% |
| 2017 Q2 | -8.62 Million AUD | 0.0% |
| 2017 Q3 | -7.53 Million AUD | 12.68% |
| 2017 Q4 | -7.53 Million AUD | 0.0% |
| 2017 Q1 | -8.62 Million AUD | -62.65% |
| 2016 Q1 | -3.6 Million AUD | 29.93% |
| 2016 Q3 | -5.3 Million AUD | -47.09% |
| 2016 FY | -5.3 Million AUD | -3.07% |
| 2016 Q4 | -5.3 Million AUD | 0.0% |
| 2016 Q2 | -3.6 Million AUD | 0.0% |
| 2015 Q2 | -6.97 Million AUD | 0.0% |
| 2015 FY | -5.14 Million AUD | -12.95% |
| 2015 Q4 | -5.14 Million AUD | 0.0% |
| 2015 Q3 | -5.14 Million AUD | 26.22% |
| 2015 Q1 | -6.97 Million AUD | -53.09% |
| 2014 Q1 | -5.39 Million AUD | -19.74% |
| 2014 FY | -4.55 Million AUD | -1.12% |
| 2014 Q4 | -4.55 Million AUD | 0.0% |
| 2014 Q3 | -4.55 Million AUD | 15.55% |
| 2014 Q2 | -5.39 Million AUD | 0.0% |
| 2013 FY | -4.5 Million AUD | -42.08% |
| 2013 Q4 | -4.5 Million AUD | 0.0% |
| 2013 Q3 | -4.5 Million AUD | 0.0% |
| 2012 FY | -3.17 Million AUD | 29.63% |
| 2012 Q4 | -3.17 Million AUD | 0.0% |
| 2011 FY | -4.5 Million AUD | -44.65% |
| 2011 Q4 | -4.5 Million AUD | 0.0% |
| 2010 FY | -3.11 Million AUD | -9.96% |
| 2010 Q4 | -3.11 Million AUD | 0.0% |
| 2009 Q4 | -2.83 Million AUD | 0.0% |
| 2009 FY | -2.83 Million AUD | 73.54% |
| 2008 Q4 | -10.7 Million AUD | 0.0% |
| 2008 FY | -10.7 Million AUD | -1771.78% |
| 2007 Q4 | -571.78 Thousand AUD | 0.0% |
| 2007 FY | -571.78 Thousand AUD | 43.75% |
| 2006 Q4 | -1.01 Million AUD | 0.0% |
| 2006 FY | -1.01 Million AUD | 61.23% |
| 2005 FY | -2.62 Million AUD | -560.46% |
| 2005 Q4 | -2.62 Million AUD | 0.0% |
| 2004 FY | 569.38 Thousand AUD | 0.0% |
| 2004 Q4 | 569.38 Thousand AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 119.72% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 175.483% |
| SQZ Biotechnologies Company | -36.23 Million USD | 91.422% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 107.264% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 50.696% |
| Mesoblast Limited | 55.85 Million USD | 105.565% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 435.252% |
| Genus plc | 190.6 Million USD | 101.631% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 239.027% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 356.071% |
| Marizyme, Inc. | 18.56 Million USD | 116.74% |
| ContraFect Corporation | -6.02 Million USD | 48.417% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 557.12% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 2408.702% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 369.027% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 238.63% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 156.497% |
| MultiCell Technologies, Inc. | 90.04 USD | 3452357.885% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -323.502% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 124.011% |
| EV Biologics, Inc. | 1.36 Million USD | 327.228% |
| Q BioMed Inc. | 4.06 Million USD | 176.562% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 110.174% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 599.453% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 408.461% |
| Biomind Labs Inc. | 711.4 Thousand USD | 536.942% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 102.831% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 124.272% |
| Skye Bioscience, Inc. | -5.72 Million USD | 45.67% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 461.342% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 2323.408% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 155.032% |
| IMV Inc. | 7.67 Million USD | 140.524% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 15746.112% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 241.164% |
| GB Sciences, Inc. | 1.74 Million USD | 277.896% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -1591.304% |
| HST Global, Inc. | 96.79 Thousand USD | 3311.403% |
| CSL Limited | 10.52 Billion USD | 100.03% |
| Halberd Corporation | 144.72 Thousand USD | 2247.866% |
| Enzolytics Inc. | 981.65 Thousand USD | 416.65% |
| Resverlogix Corp. | 6.45 Million USD | 148.185% |
| Affymax, Inc. | -5.59 Million USD | 44.463% |
| SYBLEU INC | 473.71 Thousand USD | 756.179% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -361.813% |
| argenx SE | -2.02 Billion USD | 99.847% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 107.157% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 93.388% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 214.76% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 64.837% |
| AVAX Technologies, Inc. | -5.9 Million USD | 47.344% |
| Zenith Capital Corp. | 10.06 Thousand USD | 30986.457% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.707% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 1650.857% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 230.275% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 1989.509% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 105.134% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 255.468% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | -20.948% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 964.144% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 115.331% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -16869.172% |
| BioStem Technologies, Inc. | 4.47 Million USD | 169.508% |
| ONE Bio Corp. | 9.04 Million USD | 134.385% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 1644.522% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -237183.435% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 1607.351% |
| Agentix Corp. | 37.63 Thousand USD | 8360.246% |
| LadRx Corporation | -2.03 Million USD | -52.637% |
| Cell Source, Inc. | 9.23 Million USD | 133.67% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -15131.346% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 589.385% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 589.385% |
| NovAccess Global Inc. | 2.17 Million USD | 242.688% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 143.96% |
| Itoco Inc. | 228.3 Thousand USD | 1461.518% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 2385.783% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 162.708% |
| Kadimastem Ltd | -253.1 Thousand USD | -1128.127% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 873.528% |
| CytoDyn Inc. | 20.26 Million USD | 115.341% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -480334.776% |
| Mobile Lads Corp. | 484.23 Thousand USD | 741.926% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -33437.969% |
| Qrons Inc. | 351.42 Thousand USD | 984.512% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 140.338% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -1145.258% |
| Rebus Holdings, Inc. | 305 Thousand USD | 1119.152% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 169.742% |
| International Stem Cell Corporation | 2.59 Million USD | 220.016% |
| Bioxytran, Inc. | 1.89 Million USD | 263.694% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 5080.394% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 242.529% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 190.519% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 136.343% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 502.328% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -148.673% |
| Neutra Corp. | 52.18 Thousand USD | 6056.298% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -24.886% |
| PureTech Health plc | -167.19 Million USD | 98.141% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -1169.217% |
| IXICO plc | -4.44 Million USD | 30.063% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 123.515% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 105.667% |
| CSL Limited | 10.52 Billion USD | 100.03% |
| Cellectis S.A. | -43.81 Million USD | 92.906% |